Potential Treatment for patients with solid tumors

Pierre Fabre's IND filing for PFL-002/VERT-002

Males doctor examining brain MR, representational image. Photo iStock

Pierre Fabre Laboratories recently announced the filing of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a first-in-human (FIH) Phase I/II clinical trial with PFL-002/VERT-002 for solid tumors including non-small cell lung cancer (NSCLC).

The PFL-002/VERT-002 Phase I/II trial is a multi-center, international study aimed at assessing the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of PFL-002/VERT-002 in NSCLC patients with MET alterations, including those acquired as a resistance mechanism to other treatments. The FDA will review the application and determine its acceptability.

“Ware looking forward to initiating the first-in-human trial of PFL-002/VERT-002 later this year. We are confident that this new drug holds significant promise, as a novel therapeutic option with a differentiated mechanism of action, for patients facing MET-altered solid tumors, including NSCLC” said Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories.


Please enter your comment!
Please enter your name here